October 05, 2022
The ONCOS-102 phase 1b melanoma study selected for oral presentation at the SITC 2022 annual meeting
Media
October 04, 2022
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
October 03, 2022
Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market
September 27, 2022
Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA
September 23, 2022
Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC
September 22, 2022
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
September 22, 2022
Vicore announces that C21 promotes vascular function in humans
September 21, 2022
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
September 20, 2022
Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published
September 15, 2022
Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease